Griffith, Monash researchers behind new start-up
04 September, 2002 by Pete YoungTwo leading Australian scientists - Prof Mark von Itzstein and Prof Ross Coppel - have helped form a new company to deliver novel pharmaceuticals for use against drug-resistant bacteria.
Monash IRD creates mouse model for neuro disease
04 September, 2002 by Melissa TrudingerResearchers at the Monash Institute of Reproduction and Development have succeeded in creating a transgenic mouse model for Kennedy disease, a neurodegenerative disease that affects approximately 1 in 50,000 men.
Autogen presents diabetes findings at Brazil conference
29 August, 2002 by Melissa TrudingerThe discovery of a gene that links type 2 diabetes and heart disease could lead to the development of new therapeutic treatments for diabetes, according to Victorian biotech Autogen.
Good results boost AustCancer breast cancer program
28 August, 2002 by Melissa TrudingerWA-headquartered Australian Cancer Technology has accelerated its breast cancer therapeutic program after reporting good first-stage results.
$118m for institutes in NHMRC program grants
28 August, 2002 by Melissa TrudingerSixteen National Health and Medical Research Council program grants worth more than $118 million have been awarded to research teams at some of Australia's top research institutions.
Metabolic nets BIF grant for pre-clinical studies
23 August, 2002 by Melissa TrudingerMelbourne company Metabolic Pharmaceuticals has received a BIF grant of $234,700 to pursue pre-clinical studies on an orally available iron-chelating compound.
Malaria vaccine breakthrough for WEHI
15 August, 2002 by Melissa TrudingerGroundbreaking research on a malaria toxin could lead to the development of an effective vaccine for the deadly disease according to a paper published in the August 15 issue of Nature.
Papillomavirus vaccine looking positive after Phase I
14 August, 2002 by Pete YoungPromising results have emerged from a two-year Phase I human clinical trial of an Australian-developed therapeutic vaccine targeting cervical cancer.
Cell death key discovered by Monash Institute
07 August, 2002 by Tanya HollisMelbourne researchers have uncovered a new genetic player in programmed cell death, offering a fresh target for potential cancer therapies.
Monash researchers in osteoporosis find
06 August, 2002 by Tanya HollisAn international collaboration including Melbourne researchers has uncovered two reasons for calcium deposits in bones and joints, setting the foundation for new osteoporosis therapies.
Starpharma gains new US patent approval
05 August, 2002 by Tanya HollisNanotechnology drug developer Starpharma Pooled Development today announced it had gained approval for a United States patent over its dendrimer-based anti-cancer products.
pSivida in joint venture with Singapore hospital
30 July, 2002 by Pete YoungThe first joint venture equity pact struck by Singapore's largest hospital could open a fast track to market for anti-cancer technology from Perth biotech pSivida.
Novogen subsidiary signs with NIH agency for cancer trials
25 July, 2002 by Tanya HollisMarshall Edwards Inc, a listed subsidiary of Australian pharma Novogen, has signed a cooperative agreement with a National Institutes of Health agency in the United States to examine clinical applications for its anti-cancer compound, phenoxodiol.
Making things better
24 July, 2002 by Tanya HollisProf Bob Williamson's involvement in genetics goes back to a time when few people understood the possibilities of the science.
New UQ research complex
17 July, 2002 by Melissa TrudingerA new research complex, the Centres for Health Research, was officially opened on Monday at the Princess Alexandra Hospital to house 140 scientists from the University of Queensland and the Princess Alexandra Hospital.
